Everest Medicines Announces Participation in Upcoming Investor Conferences

Everest Medicines Announces Participation in Upcoming Investor Conferences

SHANGHAI, July 27, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...

Ohmyhome Ltd Announces Pricing of $4 Million Registered Direct Offering

Ohmyhome Ltd Announces Pricing of $4 Million Registered Direct Offering

SINGAPORE, July 27, 2026 /PRNewswire/ -- Ohmyhome Ltd (NASDAQ: OMH) (the "Company"), a data- and technology-driven digital marketing company delivering multi-channel marketing and content solutions for advertisers, today announced that it has...

HTCO Announces Ten-Year Extension of Singapore MSI-AIS Maritime Tax Exemption Through 2035

HTCO Announces Ten-Year Extension of Singapore MSI-AIS Maritime Tax Exemption Through 2035

MSI-AIS Award Extended Through 2035, Providing Long-Term Tax Certainty and Enhancing Competitive Position in Global Shipping NEW YORK, July 27, 2026 /PRNewswire/ -- High-Trend International Group (NASDAQ: HTCO) ("HTCO" or the "Company"), a global...

Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors

Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors

Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma...

Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model. -Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be...

Russell Reynolds Associates Announces Nick Fletcher as Australia Country Leader

Russell Reynolds Associates Announces Nick Fletcher as Australia Country Leader

SYDNEY, July 27, 2026 /PRNewswire/ --Russell Reynolds Associates today announced that Nick Fletcher, based in Melbourne and Sydney, has been appointed Australia Country Leader, succeeding Alistair Macrae, who moves into the role of Head of Asia...

Hyundai Motor Group Executive Chair Euisun Chung Announces Physical AI Vision at San Francisco AI Summit

Hyundai Motor Group Executive Chair Euisun Chung Announces Physical AI Vision at San Francisco AI Summit

Hyundai Motor Group shares roadmap for realizing its Physical AI vision and collaboration strategy with global tech leaders at the San Francisco AI Summit Executive Chair Euisun Chung presented, "Hyundai Motor Group is evolving beyond the...

MaxsMaking Inc. Announces Receipt of Nasdaq Delisting Determination Notice

MaxsMaking Inc. Announces Receipt of Nasdaq Delisting Determination Notice

SHANGHAI, July 24, 2026 /PRNewswire/ -- MaxsMaking Inc. (Nasdaq: MAMK) ("MaxsMaking" or the "Company"), a manufacturer of customized consumer goods with a focus on advanced technology and innovation, today announced that it received a Staff...

Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV)...

Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 24, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 88
  • menu
    menu